Literature DB >> 25174337

Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma.

Lisa M Kopp1, Chengcheng Hu, Beatriz Rozo, Andrea White-Collins, Winston W Huh, Angela Yarborough, Cynthia E Herzog, Pooja Hingorani.   

Abstract

BACKGROUND: The current standard of care for initial staging of pediatric Ewing sarcoma (EWS) patients is to obtain a bilateral bone marrow aspiration and biopsy (BMAB). The incidence of bone marrow (BM) disease in patients deemed non-metastatic by conventional and metabolic imaging and the concordance of BM positivity with other clinical characteristics are not well established. PROCEDURE: This study is a multi-institutional retrospective review of newly diagnosed EWS patients less than 40 years of age with initial staging that included imaging and BMAB.
RESULTS: A total of 116 patients were eligible with 85 patients considered non-metastatic and 31 considered metastatic by imaging. None of the 85 patients with non-metastatic disease were BMAB positive (0%; 95% CI: 0-4.2%); 13 of the 31 patients with metastases were BMAB positive (41.9%; 95% CI: 24.5-60.9%). Primary tumor size was significantly higher in patients with metastases (P = 0.017). Bone metastasis by imaging had high correlation with BMAB positivity (P = 0.0002). In addition, the number of bony metastatic sites was significantly higher in patients with a positive BMAB as compared to those with a negative BMAB (median 3.5 and 0.0, respectively; P < 0.001).
CONCLUSIONS: BMAB may not be required for initial staging of pediatric and young adult EWS patients deemed non-metastatic by imaging. In patients with metastatic disease, there is a high correlation of BM involvement with multiple bone metastases.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ewing sarcoma; bone marrow aspiration; bone marrow biopsy; bone scan; pediatrics; staging

Mesh:

Year:  2014        PMID: 25174337     DOI: 10.1002/pbc.25212

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  Treatment pathway of bone sarcoma in children, adolescents, and young adults.

Authors:  Damon R Reed; Masanori Hayashi; Lars Wagner; Odion Binitie; Diana A Steppan; Andrew S Brohl; Eric T Shinohara; Julia A Bridge; David M Loeb; Scott C Borinstein; Michael S Isakoff
Journal:  Cancer       Date:  2017-03-21       Impact factor: 6.860

2.  Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.

Authors:  Uwe Thiel; Angela Wawer; Irene von Luettichau; Hans-Ulrich Bender; Franziska Blaeschke; Thomas G P Grunewald; Marc Steinborn; Barbara Röper; Halvard Bonig; Thomas Klingebiel; Peter Bader; Ewa Koscielniak; Michael Paulussen; Uta Dirksen; Heribert Juergens; Hans-Jochem Kolb; Stefan E G Burdach
Journal:  Oncotarget       Date:  2016-10-25

3.  Futility versus utility of marrow assessment in initial Ewing sarcoma staging workup.

Authors:  Peter M Anderson
Journal:  Pediatr Blood Cancer       Date:  2014-10-12       Impact factor: 3.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.